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Introduction
Liver cancer is the fifth most common malignancy, affecting approximately one million people around the world every year and is ranked second among all cancer-related deaths, causing more than 690,000 deaths annually [1] . China has the highest liver cancer incidence in the world, accounting for 45% and 53% of the worldwide morbidity and mortality, respectively [2, 3] . Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Most cases of HCC are secondary to either a viral hepatitis infection (hepatitis B or C) or cirrhosis, which is mainly induced by alcoholism [4] . A number of classical anticancer drugs, interferons and hormone drugs as well as some cytotoxic compounds, such as adriamycin are currently used for the treatment of HCC. However, most of these drugs show poor treatment efficacies with strong toxic and side effects [5] . Currently, only sorafenib, a tyrosine kinase inhibitor that has been shown to significantly block tumour growth, is approved for patients with advanced HCC [6] . Therefore, the development of novel chemotherapeutic agents is urgently needed.
23-Hydroxybetulinic acid (23-HBA) is a lupane-type pentacyclic triterpene from the Chinese medicinal herb Pulsatilla chinensis and has been found to exhibit antitumour activity in vitro and in vivo [7] [8] [9] [10] . Several reports have indicated that the antineoplastic mechanisms of 23-HBA may be associated with depolarizations of the mitochondrial membrane potential and subsequent cell apoptosis [11] [12] [13] . 23 -HBA has been shown to induce apoptosis in HL-60 cells via the inhibition of Bcl-2 expression and telomerase activity [14] . Additionally, 23-HBA is known to induce autophagic cell death in HL-60 cells via the up regulation of Beclin-1 expression [15] . Recently, we reported that 23-HBA and its bipiperidinyl derivatives reverse ABCB1-mediated multidrug resistance by simultaneously increasing the accumulation and decreasing the efflux of anti-cancer drugs [16] [17] [18] . Until now, there have been no report on the anti-hepatoma activity of 23-HBA. Given that 23-HBA has weak anticancer activity, our effort to improve its antitumour activity by structural modification has yielded a series of derivatives with enhanced bioactivity [19] [20] [21] [22] . B4G2, a derivative of 23-HBA, was previously synthesized by our group and showed a stronger anticancer activity than 23-HBA in four cancer cell lines in preliminary activity screening [20] . The present study evaluated the anti-hepatoma activity of B4G2 and its underlying molecular mechanisms. Our results demonstrated that B4G2 inhibits the growth of HCC cells and induces a reactive oxygen species (ROS)-mediated accumulation of intracellular calcium, which subsequently opens Ca 2+ -dependent permeability transition (PT) pores and leads to mitochondrial apoptosis.
Materials and Methods
Reagents B4G2 (purity>98%, Fig. 1A ) was synthesized as previously described [19] . B4G2 was dissolved in DMSO to give a stock solution of 50 mM and stored at -20°C. An anti-caspase-8 antibody, 3-(4, 5-dimethylthiazol-2-y1)-2, 5-diphenyl tetrazolium bromide (MTT), propidium iodide (PI) and 2'-(4-hydroxyphenyl)-5-(4-methyl-1-piperazinyl)-2,5'-bi-1H-benzimidazole trihydrochloride hydrate bisbenzimide (Hoechst 33258) were purchased from Sigma (St. Louis, MO, USA). An Annexin V-FITC/PI staining assay kit was obtained from Trevigen, Inc. (Gaithersburg, MD, USA). We purchased 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolylcarbocyanine iodide (JC-1) and N-(4-(6-((acetyloxy)methoxy)-2,7-dichloro-3-oxo-3H-xanthen-9-yl)-2-(2-(2-(bis(2-((aceyloxy)methoxy)-2-oxyethyl)amino)-5-methylphenoxy)ethoxy)phenyl)-N-(2-((acetyloxy) methoxy)-2-oxyethyl)-(acetyloxy) methyl ester (Fluo-3-AM) from Invitrogen (Eugene, OR, USA). Z-ValAla-Asp-CH2F (Z-VAD-FMK) was obtained from Beyotime Institute of Biotechnology (Shanghai, China). Antibodies against caspase-3 and caspase-9 were purchased from Cell Signalling Technology (Beverly, MA, USA). We purchased 2', 7'-dichlorofluorescein diacetate (H2DCFDA) and antibodies against Bcl-2, Bax and PARP from Santa Cruz Biotechnology (Santa Cruz, CA, USA). An antibody against cytochrome c was obtained from Epitomics (Burlingame, CA, USA). N-acetyl-L-cysteine (NAC) was purchased from Qiyun Biotechnology Company (Guangzhou, Guangdong, China).
MTT assay in vitro
The cytotoxicity of B4G2 in the HCC cells (HepG2, HepG2/ADM, Hep3B and Bel-7402) was measured using the MTT assay as previously described [23] . Cells were seeded in 96-well microplates at a density of 5000 cells/well and cultured for 24 h. The cells were then treated with various concentrations of B4G2 for 24, 48 and 72 h. MTT (30 μL; 5 mg/mL) was then added to the cells, and the cells were incubated for an additional 4 h. The medium was removed and 100 μL of DMSO was added to each well. The optical density was measured at 595 nm using a DTX 880 microplate reader (Beckman Coulter, CA, USA).
Colony formation assay
HepG2 cells were seeded in 6-well microplates at a density of 300 cells/well and cultured for 24 h. The cells were then treated with various concentrations of B4G2 for 48 h and maintained in fresh medium in a humidified atmosphere of 5% CO 2 at 37°C for 10 days. The cells were then fixed in methanol at -20°C for 10 min and stained with 1% crystal violet for 20 min. After being washed twice with phosphate-buffered saline (PBS), visible colonies were manually counted.
Cell cycle analysis
Cell cycle distribution was analysed as described previously [24] . Briefly, HepG2 cells were treated with or without B4G2 at various concentrations, collected, washed twice with PBS and fixed in ice-cold 70% (v/v) ethanol at 4°C overnight. After centrifugation at 2500 rpm, cell pellets were resuspended in 1 mL PBS containing 0.02 mg/mL PI and 0.1 mg/mL RNase A, and the samples were incubated at 37 °C for 30 min in darkness. DNA content was measured by Epics XL Flow Cytometry (Beckman Coulter) (Ex=488 nm and Em=620 nm).
Hoechst 33258 staining
HepG2 cells treated with or without B4G2 for 48 h were stained with Hoechst 33258 (10 mg/mL in PBS) for 30 min at 37°C in darkness and then washed twice with PBS. Cell morphology was observed using a KX41 fluorescence microscope (Olympus, Tokyo, Japan) (Ex=350 nm and Em=460 nm).
Ultrastructural observation by transmission electron microscopy
HepG2 cells treated with B4G2 were first fixed in ice-cold 4% glutaraldehyde at 4°C overnight. The cells were then washed twice with PBS, post-fixed in 1% osmium tetroxide for 1 h and dehydrated in a graded series of ethanol and acetone. The cells were then polymerized by epoxy resin. Ultra-thin sections were cut and stained with aqueous uranyl acetate and lead citrate. Finally, the ultrastructure of the cells was examined using a JEM 1400 transmission electron microscope (Philips, Eindhoven, Netherlands).
Annexin-V-FITC/PI staining assay
HepG2 cells were stained with 500 μL of labelling solution containing 5 μL Annexin-V-FITC and 10 μL PI for 15 min at room temperature in darkness. The fluorescence of the sample was detected by Epics XL Flow Cytometry (Beckman Coulter) (Ex=488 nm and Em=525 nm for Annexin V-FITC; Ex=488 nm and Em=620 nm for PI).
Detection of mitochondrial membrane potential (ΔΨ m )
Changes in the mitochondrial membrane potential were detected using JC-1, a fluorescent dye that accumulates in mitochondria, as previously described [23, 24] . Cells with high mitochondrial membrane
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Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry potential were indicated by red fluorescence emitted from J-aggregates, whereas cells with depolarized mitochondria were detected by the green fluorescence emitted from JC-1 monomers. HepG2 cells treated with or without B4G2 at various concentrations were collected by trypsinization, and then washed twice with PBS. After centrifugation at 2500 rpm, cell pellets were resuspended in 500 μL of JC-1 solution (5 μM JC-1 in PBS) and incubated for 15 min at 37°C in darkness. The mitochondrial membrane potential was measured by Epics XL Flow Cytometry (Beckman Coulter, USA) (Ex=488 nm and Em=575 nm for J-aggregates; Ex=488 nm and Em=525 nm for JC-1 monomers).
Measurement of intracellular calcium level and ROS
For the observation of intracellular calcium level, HepG2 cells were seeded in 6-well plates and incubated overnight for attachment. Cells were treated with B4G2 (4 μM) for 0.5, 1 and 4 h. After being washed three times with PBS, cells were incubated with Fluo-3-AM (10 μM) for 30 min at 37°C in darkness. The cells were then washed with PBS after the Fluo-3-AM was removed. The green fluorescence was observed using a KX41 fluorescence microscope (Olympus, Japan) (Ex=488 nm and Em=535 nm). For the quantification of intracellular calcium levels and ROS, HepG2 cells were seeded in black 96-well microplates (transparent bottom) at a density of 20,000 cells/well and cultured with B4G2 for specified time intervals. The cells were then treated with Fluo-3-AM (10 μM) or H2DCFDA (10 μM) for 30 min at 37°C in darkness. The intensity of the fluorescence was measured using a DTX 880 microplate reader (Beckman Coulter, USA) (Ex=488 nm and Em=535 nm).
Western blotting
The preparation of total protein lysates and western blot analyses were performed as previously described [24] . HepG2 cells were collected by trypsinization and washed twice with ice-cold PBS. Total cellular protein was extracted using RIPA lysis buffer (1% Nonidet-P40, 0.5% sodium deoxycholate and 0.1% SDS in PBS) with 1 mM phenylmethanesulfonyl fluoride (PMSF), 1× phosphatase inhibitor and 1× protease inhibitor on ice for 30 min. The lysates were centrifuged at 14,000 rpm for 10 min to obtain supernatants. For cytosol fraction preparation, cells were treated with cytoplasmic protein lysis buffer (10 mM HEPES, pH=7.9; 10 mM KCl; 0.1 mM EDTA; and 0.4% Nonidet-P40) containing 1 mM PMSF, 1× phosphatase inhibitor and 1× protease inhibitor on ice for 30 min. After centrifugation at 14,000 rpm for 1 min at 4°C, the supernatant was collected as cytoplasmic protein. The protein concentration was quantified using a BCA assay kit (Thermo Scientific, USA). Proteins (30-50 μg) were resolved on SDS-PAGE gels and then transferred to polyvinylidene fluoride (PVDF) membranes. The membranes were blocked with 5% nonfat milk or bovine serum albumin (BSA) in Tris-buffered saline (50 mM Tris and 150 mM NaCl, pH 7.6) with 0.05% Tween-20 (TBS-T) and probed overnight with primary antibodies at 4°C. The membranes were then incubated with secondary antibodies conjugated to horseradish peroxidase (HRP) at room temperature for 1 h. An enhanced chemiluminescence kit (Thermo Scientific, MA, USA) and an X-ray film processor (Kodak X-102, NY, USA) were used to visualize the bands.
Statistical analysis
Each experiment was performed at least three times, and the results are represented as the mean ± standard deviation (SD). GraphPad Prism 4.0 was used for statistical analyses. A difference was considered significant when P<0.05.
Results

B4G2 inhibits the growth of HCC cells
Four HCC cell lines, HepG2, HepG2/ADM, Hep3B and Bel-7402, were used to evaluate the cytotoxicity of B4G2. As shown in Table 1 , B4G2 significantly reduced the cell viability of the four HCC cell lines. HepG2 cells were sensitive to B4G2, which inhibited the survival of HepG2 cells in a concentration-dependent manner at 48 and 72 h (Fig. 1B) . B4G2 also had an inhibitory effect on the viability of HepG2/ADM cells, in which doxorubicin was ineffective (Table 1) . B4G2 showed lower toxicity to normal cell line LO2 than the human cancer cells ( Table 1 ). The colony formation assay also confirmed that B4G2 inhibited the proliferation of HepG2 cells in a concentration-dependent manner (Fig. 1C) . We next investigated the molecular mechanisms underlying B4G2-induced cell death in HepG2 cells.
B4G2 induces apoptosis in HepG2 cells
To determine whether B4G2-induced cell death was related to cell cycle arrest, a cell cycle analysis was performed. As shown in Fig. 2A , HepG2 cells treated with different concentrations of B4G2 resulted in the accumulation of cells in the sub-G 1 phase of the cell cycle in a concentration-dependent manner at 48 h. Because the sub-G 1 phase of cell cycle may be attributed to the induction of either apoptosis or necrosis, morphological changes were examined to determine whether B4G2 induced apoptotic cell death. After treatment with B4G2 for 48 h, HepG2 cells showed both cell shrinkage and chromatin condensation as indicated by strong bright blue fluorescence, whereas control cells showed normal morphologies with weak blue fluorescence (Fig. 2B) . Additionally, a few specific apoptotic characteristics, including cell volume reduction, plasma membrane blebbing, nuclear membrane shrinkage, chromatin condensation, chromatin margination and nuclear fragmentation, were observed by transmission electron microscopy in B4G2-treated HepG2 cells (Fig. 2C) . The quantification of apoptotic cells by the Annexin V/PI double staining assay also showed that the B4G2 treatment led to significant increases in cell populations in the early apoptotic phases, ranging from 25.0% to 34.5% compared with a 3.8% increase in the vehicle-treated control (Fig. 2D) . Collectively, these data indicated that B4G2 induces apoptotic cell death in HepG2 cells. decreases of pro-caspase-9 and pro-caspase-3 expression levels (Fig. 3A) . PARP, which is a protein associated with DNA repair and considered as a hallmark of apoptosis, was also found to be cleaved in response to the activation of caspase-3 (Fig. 3A) . However, a pretreatment with Z-VAD-FMK, a broad spectrum inhibitor of caspases, did not rescue cells from apoptosis caused by B4G2 (Fig. 3B) . These results indicated that the mitochondrial pathway, rather than the death receptor pathway, may be involved in a caspase-independent apoptosis mechanism induced by B4G2. To further confirm this hypothesis, changes in the mitochondrial membrane potential and cytosolic levels of cytochrome c (Cyto c), which are 
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B4G2 induces the generation of ROS to mediate the increase of intracellular calcium levels
Given the disruption of the mitochondrial potential induced by B4G2, the intracellular calcium levels, which regulate mitochondrial function, were examined. The occurrence and intensity of green fluorescence were both markedly increased by extending the duration of B4G2 treatment from 0.5 to 4 h, which indicated an overloading of calcium in the cytoplasmic fraction (Fig. 5A) . ROS, important markers of mitochondrial damage, were also detected. As indicated in Fig. 5B and C, the exposure to B4G2 also induced an increase of intracellular ROS as early as 0.5 h, which was abrogated in the presence of the NAC, a ROS scavenger. Moreover, pre- treatment with NAC decreased the B4G2-induced accumulation of intracellular calcium (Fig.  5D) , indicating that the release of ROS elevated the intracellular calcium levels.
Blockage of ROS attenuates B4G2-induced mitochondrial apoptosis
To further confirm the role of ROS as an initiator in B4G2-induced apoptosis, cells were preincubated with 20 mM NAC prior to B4G2 treatment. As shown in Fig. 6 , NAC pretreatment markedly increased cell viability compared with B4G2 treatment alone. NAC pre-treatment also attenuated the B4G2-induced collapse of the mitochondrial membrane potential, increased the population of Annexin V-positive cells and increased the specific cleavage of PARP. These results suggested that ROS initiate the B4G2-induced mitochondrial apoptosis in HepG2 cells.
Discussion
Natural products and their derivatives have been considered major sources of chemotherapeutic drugs and leading drugs [26] . 23-HBA, a derivative of the Chinese medicinal herb Pulsatilla chinensis, has weak antitumour activity in vitro and in vivo [8, 9, [11] [12] [13] [14] . Therefore, our group chemically modified 23-HBA by introducing a nitrogenic side chain at the C28 position to obtain B4G2, which was shown to have remarkably improved anticancer activity [10] . In the present study, we report the effects of B4G2 on HBV-infected HCC cells, i.e., HepG2, Bel-7402 and Hep3B cells, and on multidrug resistant HepG2/ADM cells. The results indicated the potential of B4G2 in the treatment of various types of HCC. Based on the present data, an in vivo study will be performed to determine whether B4G2 can inhibit tumour growth in a nude mouse xenograft model. Additionally, the in vivo toxicity of B4G2 towards normal tissues (e.g., heart, lung, liver, kidney and spleen) should be determined to further develop B4G2 as a chemotherapeutic agent for preclinical studies. Many studies have shown that the induction of apoptosis in cancer cells is crucial to the killing mechanisms of most anti-cancer treatments including chemotherapy, immunotherapy and cytokine therapy [27, 28] . At least two main pathways have been identified that lead to apoptosis, namely the death receptor pathway and the mitochondrial pathway [27] . Abundant studies have demonstrated that betulinic acid (BA) induces apoptosis through the mitochondrial pathway, as evidenced by mitochondrial membrane potential depolarizations, Cyto c release from mitochondria, Smac release from mitochondria and increased levels of proteolytically cleaved caspase-3 and PARP [29] . However, Liby reported that TP-295 and TP-296 (BA derivatives that contain a methoxycarbonyl group in ring A) activate apoptosis through the extrinsic death receptor-mediated pathway [30] in Bax/Bak -/-cells. In our research, typical apoptotic morphological characteristics, including an increase in the sub-G1 phase of the cell cycle, the appearance of Annexin V-positive cells and the cleavage of PARP, were found to be responses to the effects of B4G2, which suggested that B4G2 decreases the viability of HepG2 cells through the induction of apoptosis. Moreover, in B4G2-treated HepG2 cells, B4G2 activated the mitochondrial apoptotic pathway, as supported by the decrease in the mitochondrial membrane potential, the release of Cyto c, and the activations of caspase-9 and caspase-3. However, caspase-8 expression remained unchanged, and the pan-caspase inhibitor had no effect on B4G2-induced cell death. These results indicated that caspaseindependent mechanisms may be involved, such as the release of apoptosis-inducing factor and endonuclease G from mitochondria. Interestingly, these events are observed following increases to the mitochondrial membrane permeability. These mechanisms require further study.
Mitochondrial membrane permeability transition plays a critical role in apoptosis; this transition occurs after the opening of the PT pore [31] . The PT pore is a multi-protein complex formed between the inner and outer mitochondrial membranes. The PT pore permits water, ions and low molecular weight proteins up to 1.5 kDa to cross the mitochondrial matrix and cytosol. The pore is composed of adenine nucleotide translocase (ANT) and cyclophilin D (CyPD), which are located in the inner membrane, as well as VDAC and the recently discovered mitochondrial phosphate carrier, which are located in the outer membrane [25] . Arsenic trioxide may activate the PT pore through a direct interaction with ANT in the treatment of acute promyelocytic leukaemia [32] . This finding suggests that the regulation of the PT pore is an attractive target for cancer therapeutics. Recent research has indicated that Bak and Bax interact with ANT and/or VDAC, and this interaction results in a sudden permeability increase in the inner mitochondrial membrane. Subsequently, mitochondrial functions are disrupted and proapoptotic proteins are released, including Cyto c, apoptosisinducing factor and endonuclease G, leading to apoptosis [33] . Moreover, anti-apoptotic Bcl-2 family members, such as Bcl-2 and Bcl-xL, could block the amplification in mitochondrial membrane permeability by directly inhibiting VDAC or heterodimerizing pro-apoptotic Bcl-2 family members. Other Bcl-2 proteins may also form autonomous channels independent of the PT pore due to their ability to oligomerize into ion channel structures that increase the depolarizing effect induced by PT [25] . Fulda found that the overexpression of the antiapoptotic proteins, Bcl-2 or Bcl-xL, counteracted BA-induced apoptosis [34] . Moreover, Mullauer reported that BA altered the levels of Bax and Bcl-2 proteins but did not alter the levels of Bcl-xS, Bcl-xL, Bax and Bak [35] . Mullauer further reported that BA affected mitochondria and induced the release of Cyto c directly via the PT pore. In our study, we found that the expressions Bcl-2 and Bax significantly changed after B4G2 treatment, suggesting that Bcl-2 and Bax are involved in the regulation of the mitochondrial membrane permeability. Additionally, the roles of the other Bcl-2 family members, such as Bak or Bcl-xL, in the formation of the PT pores remain unknown. As an important modulator of PT pores, Ca 2+ induces a conformational change in the inner mitochondrial membrane by binding to the membrane and also alters the activity of mitochondrial membrane protein thiol groups. Thus, a cytosolic Ca 2+ overload can induce excessive mitochondrial Ca 2+ sequestration and can subsequently induce the opening of the PT pores [25] . In our study, B4G2 induced Ca 2+ overloading, suggesting that it may have resulted in the opening of the PT pores. Until now, the Ca 2+ -based mechanism behind the regulation of the PT pore remained undetermined [25] . The common pharmacological inhibitors of the Ca , Mn 2+ and Sr 2+ [25] . We further found that pretreatment with MgCl 2 , which inhibits the PT pore by competing with Ca 2+ for mitochondrial membrane binding sites [36] , inhibited the depolarization of the mitochondrial membrane potential and protected cells from apoptotic cell death. Thus, these data demonstrated that the PT pore plays a pivotal role in B4G2-induced apoptosis. Based on the inhibition caused by MgCl 2 , it can be concluded that B4G2 can induce the opening of the Ca 2+ -dependent PT pore. In addition to Ca
